Sunil Babu

8.1k total citations · 2 hit papers
38 papers, 1.2k citations indexed

About

Sunil Babu is a scholar working on Oncology, Pathology and Forensic Medicine and Genetics. According to data from OpenAlex, Sunil Babu has authored 38 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 12 papers in Pathology and Forensic Medicine and 10 papers in Genetics. Recurrent topics in Sunil Babu's work include Lymphoma Diagnosis and Treatment (10 papers), Chronic Lymphocytic Leukemia Research (8 papers) and CAR-T cell therapy research (8 papers). Sunil Babu is often cited by papers focused on Lymphoma Diagnosis and Treatment (10 papers), Chronic Lymphocytic Leukemia Research (8 papers) and CAR-T cell therapy research (8 papers). Sunil Babu collaborates with scholars based in United States, France and Canada. Sunil Babu's co-authors include Edward B. Garon, Jason C. Chandler, David R. Spigel, Robert M. Jotte, David Waterhouse, Chantal Loirat, Yahsou Delmas, David J. Cohen, Camille L. Bedrosian and Larry A. Greenbaum and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Sunil Babu

36 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine

2024 47 citations Keith W. Pratz, Courtney D. DiNardo et al. Blood profile →
Phase 2 Open-Label Study of Sacituzumab Govitecan as Second-Line Therapy in Patients With Extensive-Stage SCLC: Results From TROPiCS-03

2025 18 citations Afshin Dowlati, Anne C. Chiang et al. Journal of Thoracic Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sunil Babu United States	16	581	441	304	267	249	38	1.2k
T. Economopoulos Greece	18	359 0.6×	210 0.5×	254 0.8×	382 1.4×	178 0.7×	45	1.1k
Jamile M. Shammo United States	17	305 0.5×	296 0.7×	53 0.2×	874 3.3×	429 1.7×	79	1.5k
Joo-Seop Chung South Korea	14	211 0.4×	200 0.5×	106 0.3×	213 0.8×	67 0.3×	46	690
Louis Terriou France	20	177 0.3×	790 1.8×	109 0.4×	807 3.0×	138 0.6×	112	1.8k
Ayad Hamdan United States	11	116 0.2×	401 0.9×	115 0.4×	233 0.9×	54 0.2×	28	704
Agneta Zickert Sweden	28	184 0.3×	1.2k 2.6×	67 0.2×	239 0.9×	172 0.7×	56	2.0k
Joseph C. Shanahan United States	5	149 0.3×	659 1.5×	138 0.5×	113 0.4×	145 0.6×	6	1.4k
Jeffrey Schriber United States	13	333 0.6×	324 0.7×	63 0.2×	744 2.8×	136 0.5×	22	1.1k
Catherine M. Broome United States	14	170 0.3×	250 0.6×	72 0.2×	717 2.7×	62 0.2×	66	1.1k
Nikolaos Anagnostopoulos Greece	17	474 0.8×	221 0.5×	43 0.1×	753 2.8×	513 2.1×	41	1.3k

Countries citing papers authored by Sunil Babu

Since Specialization

Citations

This map shows the geographic impact of Sunil Babu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sunil Babu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sunil Babu more than expected).

Fields of papers citing papers by Sunil Babu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sunil Babu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sunil Babu. The network helps show where Sunil Babu may publish in the future.

Co-authorship network of co-authors of Sunil Babu

This figure shows the co-authorship network connecting the top 25 collaborators of Sunil Babu. A scholar is included among the top collaborators of Sunil Babu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sunil Babu. Sunil Babu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dowlati, Afshin, Anne C. Chiang, Andrés Cervantes, et al.. (2025). Phase 2 Open-Label Study of Sacituzumab Govitecan as Second-Line Therapy in Patients With Extensive-Stage SCLC: Results From TROPiCS-03. Journal of Thoracic Oncology. 20(6). 799–808. 18 indexed citations breakdown →

Cooper, Alissa J., Sreenivasa R Chandana, Muhammad Furqan, et al.. (2025). Safety and efficacy of ABBV-706, a seizure-related homolog protein 6 (SEZ6)–targeting antibody-drug conjugate, in high-grade neuroendocrine neoplasms.. Journal of Clinical Oncology. 43(16_suppl). 105–105. 2 indexed citations

Gajra, Ajeet, Sibel Blau, Julio A. Peguero, et al.. (2024). Impact of Exigent Research Network’s partnership with the Tempus AI TIME Program on the screening and matching of patients for clinical trials.. Journal of Clinical Oncology. 42(16_suppl). e13599–e13599. 1 indexed citations

Vaishampayan, Ulka N., Randy F. Sweis, Deepak Kilari, et al.. (2024). Phase 1 study (DRAGON) of SRK-181 (linavonkibart), a latent TGFβ1 inhibitor, combined with pembrolizumab in patients with anti-PD1 resistant advanced solid tumors: Updated results of expansion part.. Journal of Clinical Oncology. 42(16_suppl). 2507–2507. 1 indexed citations

Babu, Sunil, Shunsuke Kondo, Alexander I. Spira, et al.. (2023). 1076TiP First-in-human study of ABBV-514 as monotherapy and in combination with budigalimab in patients with advanced solid tumors. Annals of Oncology. 34. S647–S648. 2 indexed citations

Sweeney, Christopher J., Ivor Percent, Sunil Babu, et al.. (2022). Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research. 28(11). 2237–2247. 31 indexed citations

Pollyea, Daniel A., Keith W. Pratz, Andrew H. Wei, et al.. (2022). Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine. Clinical Cancer Research. 28(24). 5272–5279. 75 indexed citations

Danilov, Alexey V., Habte Yimer, Michael Boxer, et al.. (2021). Improvements in Health-related Quality of Life and Symptoms in Patients With Previously Untreated Chronic Lymphocytic Leukemia: Final Results From the Phase II GIBB Study of the Combination of Obinutuzumab and Bendamustine. Clinical Lymphoma Myeloma & Leukemia. 22(2). 121–128.

Olson, Daniel J., Zeynep Eroglu, Bruce Brockstein, et al.. (2021). Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma. Journal of Clinical Oncology. 39(24). 2647–2655. 136 indexed citations

10.

Durairaj, Chandrasekar, Jayeta Chakrabarti, Cristiano Ferrario, et al.. (2021). The Effect of Renal Impairment on the Pharmacokinetics and Safety of Talazoparib in Patients with Advanced Solid Tumors. Clinical Pharmacokinetics. 60(7). 921–930. 8 indexed citations

11.

Olszewski, Adam J., Abraham Avigdor, Sunil Babu, et al.. (2021). MOSUNETUZUMAB MONOTHERAPY IN ELDERLY/UNFIT PTS WITH FIRST‐LINE DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): SAFETY AND EFFICACY REMAIN PROMISING WITH DURABLE COMPLETE RESPONSES. Hematological Oncology. 39(S2). 4 indexed citations

12.

McFarlane, Joshua J., Mark D. Kochenderfer, Mark R. Olsen, et al.. (2020). Safety and Efficacy of Nivolumab in Patients With Advanced Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study. Clinical Genitourinary Cancer. 18(6). 469–476.e4. 29 indexed citations

13.

Budde, Lihua E., Sunil Babu, Izidore S. Lossos, et al.. (2019). ONGOING PHASE 1B/2 TRIALS OF MOSUNETUZUMAB INVESTIGATING NOVEL TREATMENT REGIMENS FOR PATIENTS WITH B‐CELL NON‐HODGKIN LYMPHOMA (NHL). Hematological Oncology. 37(S2). 564–566. 1 indexed citations

14.

Sharman, Jeff P., John M. Burke, Habte Yimer, et al.. (2019). Final Results from the Multicenter, Open-Label, Phase II GIBB Study of Obinutuzumab+Bendamustine in Previously Untreated Patients with Chronic Lymphocytic Leukemia. Blood. 134(Supplement_1). 4317–4317. 1 indexed citations

15.

Spigel, David R., Craig H. Reynolds, David Waterhouse, et al.. (2018). Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation — Positive Advanced Non–Small Cell Lung Cancer (CheckMate 370). Journal of Thoracic Oncology. 13(5). 682–688. 178 indexed citations

16.

Spigel, David R., Maen Hussein, David Waterhouse, et al.. (2017). Randomized results of fixed-duration (1-yr) vs continuous nivolumab in patients (pts) with advanced non-small cell lung cancer (NSCLC). Annals of Oncology. 28. v461–v461. 76 indexed citations

17.

Doyle, Kate, M. R. Rajagopal, Sunil Babu, et al.. (2017). Predictors and Prevalence of Pain and Its Management in Four Regional Cancer Hospitals in India. Journal of Global Oncology. 4(4). 1–9. 20 indexed citations

18.

Schneider, Bryan P., et al.. (2017). Exceptional Response with Immunotherapy in a Patient with Anaplastic Thyroid Cancer. The Oncologist. 22(10). 1149–1151. 54 indexed citations

19.

Sharman, Jeff P., Habte Yimer, Michael Boxer, et al.. (2017). Results of a phase II multicenter study of obinutuzumab plus bendamustine in pts with previously untreated chronic lymphocytic leukemia (CLL).. Journal of Clinical Oncology. 35(15_suppl). 7523–7523. 4 indexed citations

20.

Licht, Christoph, Larry A. Greenbaum, Petra Muus, et al.. (2015). Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney International. 87(5). 1061–1073. 296 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact